Ranbaxy Management Would Likely Rebuf Any Pfizer Offer – Analysts
This article was originally published in The Pink Sheet Daily
Executive Summary
"It's hard to see how Pfizer would run the company," one analyst said in an interview.
You may also be interested in...
Pfizer Stalls Generic Lipitor With Ranbaxy Deal
Settlement could give 20 more months of unchallenged U.S. marketing.
Pfizer Stalls Generic Lipitor With Ranbaxy Deal
Settlement could give 20 more months of unchallenged U.S. marketing.
Analysts See Daiichi Sankyo Exercising Light Control Over Ranbaxy
Parallels to Novartis-Sandoz 2005 combination seen.